Quick Answer
Entrada Therapeutics, Inc. reported Total Assets of $377.38 million for fiscal year 2025.
Entrada Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $377.38M | -28.3% |
| 2024 | $526.32M | +12.2% |
| 2023 | $469.19M | +86.1% |
| 2022 | $252.06M | -17.6% |
| 2021 | $305.83M | +602.6% |
| 2020 | $43.53M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $412.90M | -25.5% | -8.0% |
| June 30, 2025 | $448.78M | -22.9% | -7.7% |
| March 31, 2025 | $486.48M | -4.8% | -7.6% |
| December 31, 2024 | $526.32M | +12.2% | -5.1% |
| September 30, 2024 | $554.59M | +14.3% | -4.7% |
| June 30, 2024 | $581.96M | +17.8% | +13.9% |
| March 31, 2024 | $510.84M | +7.4% | +8.9% |
| December 31, 2023 | $469.19M | +86.1% | -3.3% |
- Entrada Therapeutics, Inc. showed a decrease of -28.3% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s total assets has grown by 767.0% (from $43.53 million to $377.38 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: